Leap Therapeutics, Inc. (LPTX)
NASDAQ: LPTX · Real-Time Price · USD
0.3051
-0.0115 (-3.63%)
At close: Mar 31, 2025, 4:00 PM
0.3079
+0.0028 (0.91%)
After-hours: Mar 31, 2025, 5:35 PM EDT
Leap Therapeutics Stock Forecast
LPTX's stock price has decreased by -88.29% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Leap Therapeutics stock has a target of 8.00, which predicts an increase of 2,522.09% from the current stock price of 0.31.
Analyst Consensus: Buy
* Price targets were last updated on Jun 28, 2024.
Analyst Ratings
The average analyst rating for Leap Therapeutics stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 1 | 1 | 1 |
| Buy | 2 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jan 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5.5 | Strong Buy | Reiterates | $5.5 | +1,702.69% | Jan 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5.5 | Strong Buy | Reiterates | $5.5 | +1,702.69% | Nov 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5.5 | Strong Buy | Reiterates | $5.5 | +1,702.69% | Aug 13, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.39
from -1.81
EPS Next Year
-1.35
from -1.39
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 30.3M | ||
| Avg | n/a | n/a | 9.9M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.20 | -0.83 | -0.76 | ||
| Avg | -1.39 | -1.35 | -1.27 | ||
| Low | -1.55 | -1.82 | -2.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.